CYP2C19、APOE基因在慢性血管疾病中的表征及其与抗血小板药物研究进展  

Research Progress of Characterization of CYP2C19 and APOE Genes in Chronic Vascular Diseases and Their Relationship with Antiplatelet Drug

作　　者：赖腾芳[1] 李近都 梁烨[3] 李世龙 李天资[1,4] 

机构地区：[1]右江民族医学院附属医院心血管内科,广西 百色 [2]广西医科大学附属肿瘤医院肝胆胰脾外科,广西 南宁 [3]右江民族医学院附属医院教学部,广西 百色 [4]广西根辽生物技术有限公司,广西 百色

出　　处：《亚洲心脑血管病例研究》2023年第1期1-8,共8页Asian Case Reports in Vascular Medicine

摘　　要：研究背景:研究证实阿司匹林对控制慢性血管疾病进展有显著效果,抗血小板药物应运而生。目前状况:抗血小板药物成为防治老年慢性疾病(chronic diseases of old age)不能或缺的常规性辅助治疗方案,阿司匹林、氯吡格雷、华法林、地奥斯明、利伐沙班等临床应用逐年增多,但效果参差不齐;同时,发生抗血小板药物抵抗或出血风险等不良反应的情况逐年增多,不但影响疗效,有些还威胁患者的生命,长期应用抗血小板药物的安全性问题可见一斑,安全有效的抗血小板方案备受关注。研究方法:对使用抗血小板药物的慢性血管疾病患者,观察其临床表现和治疗反应,检测其CYP2C19、APOE基因突变情况,用对照研究的方法探讨CYP2C19、APOE基因突变,慢性血管疾病临床表征及其与抗血小板药物反应的关系。结果和结论:CYP2C19和APOE基因突变在慢性血管疾病中可能有明确的临床特征,精准地掌控CYP2C19和APOE基因突变及其与临床药物精准靶点的关系,对慢性血管疾病的精准诊断和精准治疗都有现实意义。Background: Aspirin has been shown to be effective in controlling the progression of chronic vascular disease, and antiplatelet drugs have been developed. Current Status: Antiplatelet drug has become an indispensable routine adjuvant treatment for chronic diseases of old age, aspirin, clopidogrel, warfarin, diosamine, rivaroxaban and other clinical applications are increasing year by year, but the effects are mixed;side effects such as antiplatelet drug resistance and bleeding risk are increasing year by year, which not only affect the efficacy of treatment, but also threaten the lives of patients. The safety of long-term antiplatelet drug use can be seen, safe and effective antiplatelet regimens have received much attention. Methods: To observe the clinical manifestation and treatment response of the patients with chronic vascular diseases who were treated with antiplatelet drugs, and detect the mutation of CYP2C19 and APOE genes. To investigate the mutation of CYP2C19 and APOE genes with the method of control study, clinical features of chronic vascular disease and its relationship with antiplatelet drug response. Results and Conclusion: CYP2C19 and APOE gene mutations may have definite clinical characteristics in chronic vascular diseases. Accurately controlling CYP2C19 and APOE gene mutations and their relationship with clinical drug targets has practical significance for the accurate diagnosis and treatment of chronic vascular disease.

关 键 词：慢性血管疾病 CYP2C19 APOLIPOPROTEIN 基因突变 抗血小板药物 治疗反应 

分 类 号：R54[医药卫生—心血管疾病]